ARTICLE | Company News
Genmab, J&J deal
September 3, 2012 7:00 AM UTC
Genmab granted Johnson & Johnson's Janssen Biotech Inc. unit exclusive worldwide rights to develop and commercialize cancer product daratumumab ( HuMax-CD38). The human mAb against CD38 is in Phase I/...